Evidence map›Paper›PMID 32864364›Full record

ArticleClinical and experimental vaccine research2020

Antigenic properties of dense granule antigen 12 protein using bioinformatics tools in order to improve vaccine design against

Ali Dalir Ghaffari, Abdolhossein Dalimi, Fatemeh Ghaffarifar, Majid Pirestani

Open access · diamondAbstract read
In one paragraph

Article in Clinical and experimental vaccine research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Frontiers in immunology · 2025
    Article
  5. Article
  6. Article
  7. Protective efficacy ofFrontiers in cellular and infection microbiology · 2023
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ali Dalir GhaffariDepartment of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.ORCID https://orcid.org/0000-0001-9635-2876
Abdolhossein DalimiDepartment of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.ORCID https://orcid.org/0000-0001-5591-5513
Fatemeh GhaffarifarDepartment of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.ORCID 0000-0003-0891-8214
Majid PirestaniDepartment of Parasitology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.ORCID https://orcid.org/0000-0003-0046-4772
Tarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMATERIALS AND

methodsThis paper gave a comprehensive definition of the important aspects of GRA12 protein, including physico-chemical features, a transmembrane domain, subcellular position, secondary and tertiary structure, potential epitopes of B-cells and T-cells, and other important features of this protein using different and reliable bioinformatics methods to determine potential epitopes for designing of a high-efficient vaccine.

resultsThe findings showed that GRA12 protein had 53 potential post-translational modification sites. Also, only one transmembrane domain was recognized for this protein. The secondary structure of GRA12 protein comprises 35.55% alpha-helix, 19.50% extended strand, and 44.95% random coil. Moreover, several potential B- and T-cell epitopes were identified for GRA12. Based on the results of the Ramachandran plot, 79.26% of amino acid residues were located in favored, 11.85% in allowed and 8.89% in outlier regions. Furthermore, the results of the antigenicity and allergenicity assessment noted that GRA12 is immunogenic and non-allergenic.

conclusionThis research provided important basic and conceptual data on GRA12 to develop an effective vaccine against acute and chronic toxoplasmosis for further

Indexed as

Computational biologyEpitope mappingToxoplasma gondiiVaccines

Identifiers

PMID32864364
PMCPMC7445328
OpenAlexW3080900960

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.